Company intelligence / Profile preview
Tellus Therapeutics
Durham, North Carolina, USAtellustherapeutics.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Tellus Therapeutics’ lead candidate TT‑20 has shown the ability to induce regeneration of myelin-producing cells and reverse white matter injury in animal models. The company aims to address a significant unmet need for neuroprotection and repair in preterm infants at risk for lifelong neurological deficits. No clinical trial results are yet available; development remains at the preclinical stage.
- Therapeutic areas
- OtherNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Tellus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tellus Therapeutics.